Mankind Pharma : The proposed acquisition of Bharat Serum & Vaccines by Mankind Pharma for Rs 13,630 crore was approved by the Competition Commission of India (CCI) on Tuesday. After the acquisition, more than 2,500 employees of Bharat Serum will join Mankind Pharma. After this approval, shares of Mankind Pharma rose by more than 2.4% in early trade on Wednesday.

Read :- Digital Economy: India will become a trillion dollar digital economy by 2028, will benefit from 4G and 5G

The company has entered into a definitive agreement to acquire 100 per cent stake in Bharat Serum & Vaccines at an enterprise value of approximately Rs 13,630 crore.

Mankind Pharma, a listed company, is engaged in developing, manufacturing and marketing a diverse range of Pharmaceutical Ready Dosage Formulations.

On September 30, Mankind Pharma said it would raise up to Rs 10,000 crore by issuing non-convertible debentures and commercial paper.

Mankind is also involved in manufacturing and selling of active pharmaceutical ingredients (APIs), pharmaceutical intermediates and packaging products for pharmaceutical products through its subsidiaries.

Read :- Iran fired 180 ballistic missiles at Israel and Crude Oil Price went up, a blow to the hope of petrol and diesel becoming cheaper in India.

Bharat Serum & Vaccines Limited (BSV) is engaged in research, development, licensing, manufacturing, import, export, marketing and distribution of pharmaceutical formulations/FDFs, APIs, food and health supplements.